tirzepatide court case update Lilly says weight loss drug cuts heart failure risk by 38% in trial Eli Lilly sues Mochi Health

Figure 6: Drug-Induced Liver Injury

Retatrutide vs Tirzepatide: Receptor Comparison This receptor distinction is the primary reason researchers evaluate these compounds differently depending on study design

This program is for adults in Connecticut and New York who: Have a BMI that qualifies them for GLP-1 medication Want a real physician overseeing their care not a platform Care about how they look, not just what the scale says Are interested in preserving or building muscle alongside fat loss Have been put off by faceless online weight loss programs This program is not for patients whose primary concern is finding the lowest price

Bhalla S, Mehan S, Khan A, et al